Brought to you by 
Celgene options rights to Abide's serine hydrolase program; could acquire the company; deal terminated
29 Mar 2018
Executive Summary
Abide Therapeutics Inc. (developing drugs that target serine hydrolase enzymes) granted Celgene Corp. options to exclusively license rights to the start-up’s first two compounds that reach the clinic for immune diseases and inflammation. Celgene also has the option to acquire the company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene options rights to Abide's serine hydrolase program; could acquire the company; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice